Wilson R, McKillop J H, Henderson N, Pearson D W, Thomson J A
Clin Endocrinol (Oxf). 1986 Aug;25(2):151-6. doi: 10.1111/j.1365-2265.1986.tb01676.x.
In agreement with previous authors we found patients with Graves' disease to have an increased incidence of the DR 3 antigen. We could find no association, however, between the presence of the antigen and relapse after carbimazole treatment. A concordant HLA status and thyrotrophin receptor antibody (TRAb) index, obtained at either 6 or 12 months after the start of treatment could only predict cases of relapse and remission in a minority of patients making this of very limited clinical use. The TRAb index obtained at 12 months after the start of medical therapy could accurately predict cases of relapse and remission for the next 3 years in 24/30 patients studied.
与先前的作者一致，我们发现格雷夫斯病患者的DR3抗原发生率增加。然而，我们未发现抗原的存在与卡比马唑治疗后的复发之间存在关联。在治疗开始后6个月或12个月获得的一致的HLA状态和促甲状腺素受体抗体（TRAb）指数仅能预测少数患者的复发和缓解情况，临床应用非常有限。在药物治疗开始后12个月获得的TRAb指数能够准确预测所研究的30例患者中24例在接下来3年的复发和缓解情况。
